GlassScriptPhysician profile
Sneha N Patel
NPI 1932580610
$5,560.66
in general payments reported to CMS, 2019-2025
22 companies · $2,339 in 2025
The $2,339 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34.13 · 2022: $145 · 2023: $1,520 · 2024: $1,523 · 2025: $2,339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,380 · Education: $1.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,380.17 |
| Education | $1.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,457.41 | 2022-2025 | |
| Amgen INC. | $1,301.36 | 2023-2025 | Krystexxa, Enbrel, Otezla |
| Astrazeneca Pharmaceuticals LP | $534.87 | 2022-2025 | Saphnelo |
| Glaxosmithkline, LLC. | $528.01 | 2023-2025 | Benlysta |
| Pfizer INC. | $298.11 | 2023-2025 | |
| Ucb, INC. | $284.31 | 2023-2025 | Bimzelx, Cimzia |
| Organon LLC | $223.27 | 2023-2025 | Renflexis, Hadlima |
| Aurinia Pharma U.S., INC. | $157.99 | 2024-2025 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.30 | 2023-2025 | Ofev |
| Radius Health, INC. | $113.13 | 2024-2025 | Tymlos |
| Janssen Biotech, INC. | $110.23 | 2023-2025 | Tremfya |
| Lilly USA, LLC | $102.08 | 2023-2024 | Taltz |
| Horizon Therapeutics Plc | $71.67 | 2023 | Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $62.37 | 2025 | Orencia |
| Sobi, INC | $41.05 | 2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $40.52 | 2023-2025 | Actemra, Rituxan |
| Octapharma USA, INC. | $23.18 | 2024 | Octagam Immune Globulin (Human) |
| Fresenius Kabi USA, LLC | $20.00 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $17.08 | 2019 | |
| Organogenesis INC. | $17.05 | 2019 | |
| Medtronic, INC. | $16.03 | 2023 | Intellis Adaptivestim |
| Invivyd INC | $14.64 | 2025 | Pemgarda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sneha Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.